secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001193125-26-179529
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand to acquire XOMA Royalty for $39/share cash plus CVR from Janssen litigation
--------------------------------------------------------------------------------

- Cash consideration of $39.00 per XOMA Royalty share plus CVRs representing 75% of net proceeds from Janssen litigation.
- Support agreements from stockholders (~47% of shares), including BFV Partners and management, to vote in favor.
- Termination fee of $40M payable by XOMA Royalty under specified circumstances.
- Transaction subject to XOMA Royalty stockholder approval and HSR clearance; expected to close by Jan 26, 2027.
- XOMA Royalty board unanimously approved and recommends stockholders vote in favor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000119312526179529/0001193125-26-179529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000119312526179529/d143046d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-179529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer